Investors

BXQ-350 provides a value proposition that is possibly unprecedented

in how it may address significant unmet medical need across these patient populations suffering from devastating malignant disease.

BXQ-350 is a Phase 2 clinical-stage, novel, first-in-class biologic

that has a unique mechanism of action, sphingolipid metabolism modulation, thereby providing the potential for anti-tumor efficacy across a variety of advanced solid tumors paired with anti-neuropathy effect in patients suffering from CIPN (chemotherapy induced peripheral neuropathy).

Outcomes in mCRC remain dismal despite the use of Standard of Care (SOC) (FOLFOX + bevacizumab). Very few therapies have been approved in first line mCRC in the past decade

In mCRC, mPFS (median Progression Free Survival) is 6-12 months and mOS (median Overall Survival) is 24-32 months with SOC.

FOLFOX is a highly toxic chemotherapeutic regimen based on an Oxaliplatin backbone and forms part of SOC in mCRC. Oxaliplatin is commonly associated with Chemotherapy Induced Peripheral Neuropathy (CIPN), a major dose-limiting toxicity (DLT) which interrupts treatment via reduction in dose, skipping a dose or removal of Oxaliplatin in these patients.

4th

most common malignancy in the USA

150,000

new cases and 50,000 deaths per year in the USA

15%

Five-year survival for mCRC

33%

of CRC patients present with metastases

*SOURCES: Colorectal Cancer — Cancer Stat Facts and Colorectal Cancer Statistics | How Common Is Colorectal Cancer? | American Cancer Society

Pipeline in a product

BXQ-350 is the first in a new class of therapies

that has the potential to address unmet medical needs in terms of anti-tumor efficacy but also in terms of anti-neuropathy effect

Safety + tolerability

BXQ-350 has demonstrated an excellent safety and tolerability profile based on published Phase 1 clinical data. BXQ-350 had only one SAE (Severe Adverse Event) across 1100 doses administered across over 20 tumor types in Phase 1 clinical trial data.

Early efficacy data re: anti-tumor effects

Based on preliminary internal analysis of the open label portion of the Phase 1b/2 mCRC clinical trial, BXQ-350 has shown the potential in combination with SOC (FOLFOX + Bevacizumab) to have clinically meaningful outcomes, which may be especially beneficial in the first line metastatic setting.

Neuropathy indications

BXQ-350, in combination with FOLFOX + Bevacizumab, offers the opportunity to reduce intensity and delay onset of CIPN in these patients, thereby allowing them to potentially achieve higher COD (Cumulative Oxaliplatin Dose) while reducing possible dose disruption due to CIPN/ Neurotoxicity.

Non-cancer indications

While BXQ-350 was developed to target solid tumors specifically, early efficacy in neuropathy has emerged through research, primarily for Chemotherapy-induced Peripheral Neuropathy (CIPN)

CIPN is a serious clinical challenge caused by a substantial number of cytotoxic drugs, including taxanes, platinums, vinca alkaloids, bortezomib and some ADCs (Antibody Drug Conjugates.)

CIPN afflicts between 30% and 40% of patients undergoing chemotherapy. Recent studies put the prevalence of CIPN at approximately 68% when measured in the first month after chemotherapy, and 30% at and after 6 months. Debilitating symptoms persist for months to several years after treatment for many of those patients.

*SOURCES: Chemotherapy-induced peripheral neuropathy | Mechanisms of Chemotherapy-Induced Peripheral Neuropathy

BXQ-350 has shown the potential for meaningful reduction of chronic CIPN in a POC (Proof of Concept) study involving cancer patients who are post-chemotherapy Oxaliplatin (n=10) and Taxanes (n=10) in two separate arms.

BXQ-350 has also shown the potential for reduction in CIPN while co-administered with FOLFOX + Bevacizumab SOC in mCRC patients.

This may result in improved QoL (Quality of Life) and improved ability to stay on and sustain chemotoxic therapy in these patients.

Addressing an unmet medical need

BXQ-350 has potentially unprecedented anti-tumor, anti-neuropathy effects that show promise in treating cancer patients whose options for new therapies have historically been limited.

Learn More

Resources

Find case studies, abstracts, and more about the potential breakthroughs we’re pursuing

View All